Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort.
Ontology highlight
SUBMITTER: Enemark MH
PROVIDER: S-EPMC11443031 | biostudies-literature | 2024 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA